Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy.

There was a numerically superior overall response rate in patients whose tumour relapsed more than 6 months (late relapse group) compared with those whose tumour relapsed within 6 months of completing adjuvant chemotherapy (early relapse group) (39 vs 21%), although the difference did not reach statistical significance ( P =0.427; Table 2 ).

also in 111,027 other papers

In randomised phase III trials in advanced gastric cancer, FP led to improved response rates compared with 5-FU, doxorubicin and mitomycin (FAM) or 5-FU single-agent therapy ( Kim et al , 1993 ), and showed a trend towards improved response rates compared with 5-FU, doxorubicin and methotrexate (FAMTX) or etoposide, leucovorin and bolus 5-FU (ELF) ( Vanhoefer et al , 2000 ).

also in 53,322 other papers